Catalyst Wire Dossier Catalyst Wire Dossier

Januvia/Xelevia

sitagliptin · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Januvia/Xelevia, covering 2014-12-05 to 2014-12-05. Get the full timeline:

Most recent: Clinical Trial Update: An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

See pricing